- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04749368
Study to Investigate the Safety and Efficacy of BRII-835 and BRII-179 Combination Therapy Treating Chronic HBV Infection
October 9, 2023 updated by: Brii Biosciences Limited
A Phase 2 Multicenter, Randomized, Open-label Study to Investigate the Safety and Efficacy of BRII-835 (VIR-2218) and BRII-179 (VBI-2601) Combination Therapy for the Treatment of Chronic Hepatitis B Virus (HBV) Infection
This is an open label, randomized, parallel-group study to evaluate the safety and efficacy of combination treatment BRII-835 (VIR-2218) and BRII-179 (VBI-2601) in adult participants with chronic HBV infection
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
91
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New South Wales
-
Kingswood, New South Wales, Australia, 2747
- Investigative Site 61002
-
Westmead, New South Wales, Australia, 2145
- Investigative Site 61001
-
-
Queensland
-
Herston, Queensland, Australia, 4029
- Investigative Site 61004
-
-
-
-
-
Changhua, Taiwan, China, 500
- Investigative Site 88602
-
Hongkong, China
- Investigative Site 85201
-
Hongkong, China
- Investigative Site 85202
-
Hongkong, China
- Investigative Site 85203
-
Kaohsiung, Taiwan, China, 83301
- Investigative Site 88601
-
Kaohsiung, Taiwan, China
- Investigative Site 88604
-
NEW Territories, Hong Kong, China
- Investigative Site 85204
-
Taichung, Taiwan, China, 40447
- Investigative Site 88603
-
Taipei CITY, China, 10048
- Investigative Site 88605
-
-
-
-
-
Busan, Korea, Republic of, 49241
- Investigative Site 82004
-
Seongnam-si, Gyeonggi-do, Korea, Republic of, 13496
- Investigative Site 82003
-
Seoul, Korea, Republic of, 3080
- Investigative Site 82001
-
Seoul, Korea, Republic of, 3722
- Investigative Site 82005
-
Seoul, Korea, Republic of, 5505
- Investigative Site 82002
-
-
-
-
-
Auckland, New Zealand, 2025
- Investigative Site 64001
-
-
Dunedin
-
Dunedin Central, Dunedin, New Zealand, 9016
- Investigative Site 64002
-
-
-
-
-
Singapore, Singapore, 169608
- Investigative Site 65001
-
Singapore, Singapore, 529889
- Investigative Site 65002
-
-
-
-
-
Bangkok, Thailand, 10330
- Investigative Site 66001
-
Chiang Mai, Thailand, 50200
- Investigative Site 66003
-
Khon Kaen, Thailand, 40002
- Investigative Site 66002
-
Nonthaburi, Thailand, 11000
- Investigative Site 66005
-
Nonthaburi, Thailand, 11000
- Investigative Site 66006
-
Pathumthani, Thailand, 12120
- Investigative Site 66004
-
Songkhla, Thailand, 90110
- Investigative Site 66007
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Male or female aged 18 - 60
- Body mass index ≥ 18 kg/m^2 and ≤ 32 kg/m^2
- Chronic HBV infection as defined by a positive serum HBsAg for ≥ 6 months
Exclusion Criteria:
- Any clinically significant chronic or acute medical condition that makes the volunteer unsuitable for participation
- Significant fibrosis or cirrhosis
- History or evidence of drug or alcohol abuse
- History of intolerance to SC or IM injection
- History of chronic liver disease from any cause other than chronic HBV infection
- History of hepatic decompensation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort A
Participants will receive BRII-835 (VIR-2218) for 32 weeks
|
BRII-835 (VIR-2218) will be given by subcutaneous injection
|
Experimental: Cohort B
Participants will receive BRII-835 (VIR-2218) and BRII-179 (VBI-2601) with IFN-α up to Week 40
|
BRII-835 (VIR-2218) will be given by subcutaneous injection
BRII-179 (VBI-2601) with IFN-α will be co-administered by intramuscular injection
|
Experimental: Cohort C
Participant will receive BRII-835 (VIR-2218) and BRII-179 (VBI-2601) up to Week 40
|
BRII-835 (VIR-2218) will be given by subcutaneous injection
BRII-179 (VBI-2601) will be administered by intramuscular injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of participants with sustained HBsAg loss during the 48-week follow-up period after NrtI withdrawal
Time Frame: up to Week 96
|
up to Week 96
|
Number of participants with Adverse Events (AE)
Time Frame: up to Week 96
|
up to Week 96
|
Number of participants with Serious Adverse Events (SAE)
Time Frame: up to Week 96
|
up to Week 96
|
Number of participants with abnormalities in clinical laboratory tests
Time Frame: up to Week 96
|
up to Week 96
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Xiaofei Chen, Brii Biosciences Limited
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 12, 2021
Primary Completion (Actual)
July 4, 2023
Study Completion (Actual)
July 4, 2023
Study Registration Dates
First Submitted
February 7, 2021
First Submitted That Met QC Criteria
February 7, 2021
First Posted (Actual)
February 11, 2021
Study Record Updates
Last Update Posted (Actual)
October 11, 2023
Last Update Submitted That Met QC Criteria
October 9, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Disease Attributes
- Liver Diseases
- Hepatitis, Viral, Human
- Hepadnaviridae Infections
- DNA Virus Infections
- Enterovirus Infections
- Picornaviridae Infections
- Hepatitis, Chronic
- Chronic Disease
- Hepatitis B
- Hepatitis
- Hepatitis A
- Hepatitis B, Chronic
Other Study ID Numbers
- BRII-179-835-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatitis B, Chronic
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Gilead SciencesNot yet recruiting
-
Tongji HospitalGilead SciencesRecruiting
-
Jiangsu HengRui Medicine Co., Ltd.Unknown
-
Changhai HospitalCompleted
-
Zhongshan Hospital Xiamen UniversityUnknownHealthy | Chronic Hepatitis B InfectionChina
-
Tongji HospitalChia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownChronic Hepatitis b
-
Brii Biosciences LimitedVir Biotechnology, Inc.Active, not recruitingChronic Hepatitis B Virus InfectionSingapore, Thailand, Australia, China, Korea, Republic of
-
Nanfang Hospital of Southern Medical UniversityRecruiting
-
IlDong Pharmaceutical Co LtdRecruitingChronic Hepatitis bKorea, Republic of
Clinical Trials on BRII-835 (VIR-2218)
-
Vir Biotechnology, Inc.RecruitingHepatitis B, ChronicHong Kong, Korea, Republic of, Malaysia, New Zealand, Taiwan, United Kingdom, Romania, United States, Moldova, Republic of, Canada, Germany, Ukraine
-
Vir Biotechnology, Inc.RecruitingA Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218Renal ImpairmentUnited States
-
Brii Biosciences LimitedAlnylam Pharmaceuticals; Vir Biotechnology, Inc.Completed
-
Vir Biotechnology, Inc.RecruitingHepatitis D, ChronicNew Zealand, United Kingdom, Moldova, Republic of, Romania, Bulgaria, Italy, Germany, France, Netherlands
-
Vir Biotechnology, Inc.RecruitingCirrhosis | Hepatic ImpairmentUnited States
-
Vir Biotechnology, Inc.Active, not recruitingHepatitis B, ChronicHong Kong, Korea, Republic of, United Kingdom, France, Moldova, Republic of, Romania
-
Vir Biotechnology, Inc.Alnylam PharmaceuticalsCompletedChronic Hepatitis BAustralia, Hong Kong, Korea, Republic of, New Zealand, Thailand
-
Brii Biosciences LimitedVir Biotechnology, Inc.Active, not recruitingChronic Hepatitis B Virus InfectionSingapore, Thailand, Australia, China, Korea, Republic of
-
National Institute of Diabetes and Digestive and...Not yet recruiting
-
National Institute of Allergy and Infectious Diseases...Eli Lilly and Company; National Heart, Lung, and Blood Institute (NHLBI); Gla... and other collaboratorsCompletedCovid19United States, Denmark, Greece, Nigeria, Poland, Singapore, Spain, Switzerland, Uganda, United Kingdom